NSEAnalysts/Institutional Investor Meet/Con. Call Updates24 Jun 2026 · 24 Jun 2026, 01:12 pm
Analysts/Institutional Investor Meet/Con. Call Updates
Windlas Biotech Limited · WINDLAS
✦ AI Summary
Windlas Biotech Limited has informed the Exchange about the schedule of an analyst/institutional investor meeting, which will be held on July 2, 2026, and will refer to publicly available documents.
Analysis Scores
Earnings Impact5/10
Growth Catalyst5/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Windlas Biotech Limited has informed the Exchange about Schedule of meet
Attachments (1)
📄pdf
Download →
WINDLAS_24062026131209_IM_020726_1.pdf
View document text
Windlas Biotech Limited
Reg. Off.: 40/1, Mohabewala Industrial Area
Dehradun, Uttarakhand 248 110, India
Tel.:+91-135-6608000-30, Fax:+91-135-6608199
Corp. Off.: 705-706, Vatika Professional Point, Sector-66,
Golf Course Ext. Road, Gurgaon, Haryana 122 001, India
Tel.:+91-124-2821030
CIN-L74899UR2001PLC033407
June 24, 2026
To To
Listing / Compliance Department Listing / Compliance Department
BSE Limited National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G
Dalal Street, Mumbai – 400 001 Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
BSE CODE: 543329 NSE SYMBOL: WINDLAS
Dear Sir/ Madam.
Subject: Intimation of Schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations
and Disclosure Requirements), Regulations 2015
Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015, this is to inform you that the officials of our Company will be meeting Investor/Analyst,
the details of which are as under:
Date Particulars Type Mode Time
Vara Capital
Thursday, July 2, 2026 Apricus Wealth Investment Group In-person 12:00 PM
Managers
This is to further inform that the Company will be referring to all the publicly available documents for the discussions.
No unpublished price sensitive information (UPSI) will be shared during the meeting.
Please note that changes may happen due to exigencies on the part of Investors/Analysts/Company.
Kindly take the same on record.
Thanking you.
Yours faithfully,
For Windlas Biotech Limited
Ananta Narayan Panda
Company Secretary & Compliance Officer
www.windlas.com